Q-omics provides the consensus-scored TCTEX1D4 profile across patient tissues and cancer cell-line models. TCTEX1D4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, TCTEX1D4 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, TCTEX1D4 RNA expression shows 17,295 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, LUAD, and GBM as cancer lineages where TCTEX1D4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCTEX1D4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCTEX1D4 survival associations across molecular data types. TCTEX1D4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCTEX1D4 RNA expression–survival associations across cancer types. High TCTEX1D4 expression shows unfavorable associations in LGG and MESO, but favorable associations in UCEC, CESC, LUSC and ESCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for TCTEX1D4 RNA expression.
This table summarizes TCTEX1D4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TCTEX1D4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCTEX1D4 shows lower tumor expression in LUAD, LUSC, THCA and UCEC and higher tumor expression in STAD and KIRP. The LUAD box plot shows higher TCTEX1D4 RNA expression in normal versus tumor tissue (log2 FC = −1.538, t-test p < 0.001).
This table shows molecular features associated with TCTEX1D4 in patient tissues and cancer cell lines. In patient samples, TCTEX1D4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TCTEX1D4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
